Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.

A Oliver SartorJohann de BonoKim N ChiKarim FizaziKen HerrmannKambiz RahbarScott T TagawaLuke T NordquistNitin VaishampayanGhassan El-HaddadChandler H ParkTomasz M BeerAlison ArmourWendy J Pérez-ContrerasMichelle DeSilvioEuloge KpameganGermo GerickeRichard A MessmannMichael J MorrisBernd J Krausenull null

Published in: The New England journal of medicine (2021)

Radioligand therapy with 177Lu-PSMA-617 prolonged imaging-based progression-free survival and overall survival when added to standard care in patients with advanced PSMA-positive metastatic castration-resistant prostate cancer. (Funded by Endocyte, a Novartis company; VISION ClinicalTrials.gov number, NCT03511664.).

Keyphrases

free survival
pet ct
pet imaging
squamous cell carcinoma
small cell lung cancer
healthcare
palliative care
positron emission tomography
quality improvement
computed tomography
health insurance